SCHEMBL19600884

SCHEMBL19600884

CCCCOC(=O)c1ccc(N2CCN(C(=O)OC(C)(C)C)CC2)nc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.52
P2RY12 Q9H244 2/20 0.51
HRH3 Q9Y5N1 1/20 0.49
CKS1B P61024 2/20 0.49
SKP1 P63208 2/20 0.49
SKP2 Q13309 2/20 0.49
HPGD P15428 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
DDB1 Q16531 1/20 0.46
CRBN Q96SW2 1/20 0.46
TBK1 Q9UHD2 1/20 0.46
ME2 P23368 1/20 0.46
ME1 P48163 1/20 0.46
ME3 Q16798 1/20 0.46
RET P07949 3/20 0.45
MAP4K4 O95819 1/20 0.45
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2427846 0.89 P2RY12 (0.62) GPR119P2RY12HRH3CKS1BSKP1
SCHEMBL1109108 0.86 GPR119 (0.65) GPR119CKS1BSKP1SKP2HPGD
SCHEMBL20463281 0.84 MAPT (0.54) GPR119SMN1; SMN2KMT2AMEN1
SCHEMBL30313118 0.83 NPC1 (0.62) GPR119P2RY12HRH3CKS1BSKP1
SCHEMBL19283866 0.83 NPC1 (0.62) GPR119P2RY12HRH3CKS1BSKP1
SCHEMBL17107380 0.83 GPR119 (0.62) GPR119CKS1BSKP1SKP2HPGD
SCHEMBL19580854 0.82 HDAC1 (0.57) GPR119P2RY12HRH3CKS1BSKP1
SCHEMBL63484 0.81 CKS1B (0.58) GPR119HRH3CKS1BSKP1SKP2
SCHEMBL19598713 0.81 HRH3 (0.56) GPR119HRH3CKS1BSKP1SKP2
SCHEMBL31284589 0.81 HRH3 (0.56) GPR119HRH3CKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170327469-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2017-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170327469-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, MDM2, ESRRA GPR119 1030/4885P2RY12 4874/4885HRH3 3784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.